Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study

NCT06928662 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT06928662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06928662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 23, 2025
Completion date
November 29, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute undifferentiated leukemia, mixed phenotype acute leukemia, recurrent acute myeloid leukemia, recurrent acute undifferentiated leukemia, recurrent chronic myelomonocytic leukemia, recurrent mixed phenotype acute leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory acute undifferentiated leukemia, refractory chronic myelomonocytic leukemia, refractory mixed phenotype acute leukemia, refractory myelodysplastic syndrome, secondary acute myeloid leukemia